Daphné Dupéré-Richer, Ph.D.

Research Assistant Professor

Department: MD-HEMATOLOGY-ONCOLOGY-ONCOL

Business Phone: (352) 256-3151

Business Email: daphne@ufl.edu

About Daphné Dupéré-Richer

I obtained a Ph.D. in Experimental Medicine from McGill University in Montréal focusing on mechanisms of resistance to histone deacetylase inhibitors in acute myeloid leukemia. In January 2016, I joined the Licht laboratory aiming to understand how epigenetics alterations are affecting the pathogenesis of myeloma and lymphomas.

Publications

Academic Articles

Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype.
2022

Journal

Molecular cancer therapeutics.

Volume/Issue

21(4):511-521

[DOI]

10.1158/1535-7163.MCT-21-0216.

[PMID]

35086959.

3 citations PubMed Publisher’s Site
DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks.
2022

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research.

Volume/Issue

28(4):756-769

[DOI]

10.1158/1078-0432.CCR-21-2863.

[PMID]

34716195.

16 citations PubMed Publisher’s Site
PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia.
2022

Journal

Cancer discovery.

Volume/Issue

12(1):186-203

[DOI]

10.1158/2159-8290.CD-20-1771.

[PMID]

34417224.

29 citations PubMed Publisher’s Site
UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition.
2017

Journal

Cell reports.

Volume/Issue

21(3):628-640

[DOI]

10.1016/j.celrep.2017.09.078.

[PMID]

29045832.

101 citations PubMed Publisher’s Site
Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.
2017

Journal

Current opinion in hematology.

Volume/Issue

24(4):336-344

[DOI]

10.1097/MOH.0000000000000358.

[PMID]

28441149.

31 citations PubMed Publisher’s Site
H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer.
2016

Journal

Advances in cancer research.

Volume/Issue

131:59-95

[DOI]

10.1016/bs.acr.2016.05.001.

[PMID]

27451124.

52 citations PubMed Publisher’s Site

Grants

KDM6A mutation as an epigenetic driver of multiple myeloma

July 1, 2018 – June 30, 2021

Role:

Principal Investigator

Funding:

BLOOD CANCER UNITED

Contact Details

Phones:

Business:: (352) 256-3151

Emails:

Business:: daphne@ufl.edu

Addresses: